Point72 Asset Management L.P. boosted its stake in shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 67.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 681,973 shares of the biotechnology company’s stock after buying an additional 274,273 shares during the period. Point72 Asset Management L.P. owned about 1.35% of Aimmune Therapeutics worth $14,819,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in Aimmune Therapeutics during the fourth quarter valued at $1,711,000. State Street Corp raised its position in Aimmune Therapeutics by 50.5% in the fourth quarter. State Street Corp now owns 576,147 shares of the biotechnology company’s stock valued at $11,782,000 after buying an additional 193,272 shares during the period. FMR LLC raised its position in Aimmune Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,949,027 shares of the biotechnology company’s stock valued at $101,207,000 after buying an additional 37,200 shares during the period. Renaissance Technologies LLC purchased a new position in Aimmune Therapeutics during the fourth quarter valued at $2,100,000. Finally, Norges Bank purchased a new position in Aimmune Therapeutics during the fourth quarter valued at $1,258,000. 69.64% of the stock is owned by hedge funds and other institutional investors.
Shares of Aimmune Therapeutics, Inc. (AIMT) opened at 21.93 on Tuesday. The company has a 50-day moving average of $18.53 and a 200 day moving average of $19.95. Aimmune Therapeutics, Inc. has a one year low of $10.27 and a one year high of $27.31. The stock’s market cap is $1.10 billion.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.05. On average, equities analysts forecast that Aimmune Therapeutics, Inc. will post ($2.66) earnings per share for the current fiscal year.
AIMT has been the subject of several recent research reports. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 20th. Piper Jaffray Companies reissued an “overweight” rating and issued a $38.00 price target on shares of Aimmune Therapeutics in a report on Wednesday, March 22nd. Finally, ValuEngine lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 27th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $33.00.
In other news, CFO Eric Bjerkholt purchased 5,000 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was acquired at an average price of $19.84 per share, for a total transaction of $99,200.00. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares in the company, valued at approximately $99,200. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Stephen George Dilly sold 49,400 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $20.21, for a total value of $998,374.00. The disclosure for this sale can be found here. Insiders sold 125,000 shares of company stock valued at $2,574,179 in the last quarter. 24.56% of the stock is currently owned by company insiders.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.